Entrada Therapeutics reports FY2021 net loss of $51.2M; cash at $291.1M

Entrada Therapeutics, Inc.

Net loss of $18.4M in Q4'21 and $51.2M for FY2021, vs $8.7M and $26.5M in 2020.
Cash and equivalents $291.1M as of Dec 31, 2021, including $190.7M net from Nov 2021 IPO.
R&D expenses $12.4M in Q4 ($35.9M FY), up from $6.7M ($21.1M) YoY on preclinical studies.
On track to submit IND for ENTR-601-44 (DMD exon 44) in 2H 2022.
Appointed Jared Cohen, PhD, JD as General Counsel in January 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.